The effect of combined magnesium and vitamin D supplementation on vitamin D status, systemic inflammation, and blood pressure: A randomized double-blinded controlled trial.
Study Goal
The researchers aimed to determine whether a combined magnesium and vitamin D regimen was more effective than vitamin D alone in increasing serum 25OHD concentrations and improving cardiometabolic outcomes in overweight/obese individuals.
Results Summary
The combined magnesium and vitamin D group showed the greatest increase in serum 25OHD levels and a significant reduction in systolic blood pressure for those with baseline hypertension, but no significant effects on PTH or inflammatory markers were observed.
Population
Overweight or obese individuals
Effective Dosage
360 mg magnesium glycinate + 1000 IU vitamin D3, three times daily
Duration
12 weeks
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
magnesium + vitamin D (MagD; 360 mg magnesium glycinate + 1000 IU vitamin D 3 × daily) | increase | serum 25-hydroxyvitamin D (25OHD) concentrations | Owt/Ob participants | 6.3 ± 8.36 ng/mL | experienced the greatest increase | #1 |
magnesium + vitamin D (MagD; 360 mg magnesium glycinate + 1000 IU vitamin D 3 × daily) | decrease | systolic blood pressure | individuals who had a baseline systolic blood pressure of >132 mmHg in the MagD group | 7.5 ± 8.26 mmHg | decrease | #2 |
magnesium + vitamin D (MagD; 360 mg magnesium glycinate + 1000 IU vitamin D 3 × daily) | no change | serum parathyroid hormone (PTH) concentrations | Owt/Ob participants | no statistically significant change | no statistically significant treatment effects | #3 |
magnesium + vitamin D (MagD; 360 mg magnesium glycinate + 1000 IU vitamin D 3 × daily) | no change | markers of inflammation | Owt/Ob participants | no statistically significant change | no statistically significant treatment effects | #4 |
combined magnesium and vitamin D regimen | increase | serum 25OHD concentrations | Owt/Ob individuals | - | may be more effective in increasing | #5 |
OBJECTIVE: Poor vitamin D and magnesium status is observed in individuals who are overweight and obese (Owt/Ob) and is often associated with a heightened risk of cardiovascular disease. Magnesium is a cofactor that assists vitamin D metabolism. We aimed to determine the efficacy of a combined magnesium and vitamin D regimen compared with vitamin D only on increasing serum 25-hydroxyvitamin D (25OHD) concentrations and the effects of these supplements on cardiometabolic outcomes. METHODS: This 12-week double-blinded randomized controlled trial had three treatment arms: magnesium + vitamin D (MagD; 360 mg magnesium glycinate + 1000 IU vitamin D 3 × daily), vitamin D only (VitD; 1000 IU vitamin D 3 × daily), and placebo. A total of 95 Owt/Ob participants were randomized into one of these three study arms. Anthropometry, dietary intake, concentrations of serum 25OHD, serum parathyroid hormone (PTH), serum inflammatory markers, and blood pressure were obtained at baseline and week 12. RESULTS: The MagD group experienced the greatest increase in serum 25OHD concentrations (6.3 ± 8.36 ng/mL; P < 0.05). There was a decrease in systolic blood pressure (7.5 ± 8.26 mmHg; P < 0.05) for individuals who had a baseline systolic blood pressure of >132 mmHg in the MagD group. There were no statistically significant treatment effects on serum PTH concentrations and markers of inflammation. CONCLUSIONS: A combined MagD treatment may be more effective in increasing serum 25OHD concentrations compared with VitD supplementation alone in Owt/Ob individuals.